We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Combined Nicotinic Acid and Statin Treatment Reduces Atherosclerosis

By LabMedica International staff writers
Posted on 20 Nov 2009
A recent study showed that combining statin treatment to lower cholesterol levels with nicotinic acid (niacin) to raise the level of HDL (high density lipoprotein) cholesterol improved the condition of patients with established cardiovascular disease.

Investigators at Oxford University (United Kingdom) performed a double-blind, randomized, placebo-controlled study of two grams of daily modified-release nicotinic acid added to statin therapy in 71 patients with low HDL cholesterol (less than 40 mg/dl) and either type II diabetes with coronary heart disease; or carotid/peripheral atherosclerosis. More...
The primary end point of the study was the determination after one year of the change in carotid artery wall area, quantified by MRI (magnetic resonance imaging).

The investigators reported in the November 3, 2009, issue of the Journal of the American College of Cardiology that the statin-nicotinic acid regimen increased HDL cholesterol by 23% and decreased LDL (low density lipoprotein) cholesterol by 19%. At 12 months, the carotid wall area was significantly reduced compared with placebo (decreased by an average of 1.1 mm2 for those on the drug combination as opposed to an average increase in the carotid artery wall of 1.2 mm2 for those receiving a placebo).

"This is the first clear evidence that a therapy to raise levels of good cholesterol (HDL) when taken alongside statins can have a beneficial effect," said senior author Dr Robin Choudhury, professor of cardiovascular medicine at the University of Oxford. "Using MRI scans, we have shown a reduction in the size of artery walls in patients after a year of treatment with nicotinic acid. Our imaging study has identified this as a very promising new prospect for treatment, and if the findings are borne out in ongoing larger studies this could benefit large numbers of people worldwide."

"Our results are very encouraging in that they have shown a very definite potential benefit, and will certainly increase the great interest in the large outcome studies that are due to report in the next couple of years," said Dr. Choudhury. 'For years we had always been taught that atherosclerosis was a relentless progressive disease. It is exciting to see a regression in established atherosclerosis."


Related Links:
Oxford University




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.